01 22Xolair
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 2,028
2018 Revenue in Millions : 1,969
Growth (%) : 3
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 2,121
2019 Revenue in Millions : 2,194
Growth (%) : -3
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 1,251
2019 Revenue in Millions : 1,173
Growth (%) : 7
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 2,090
2020 Revenue in Millions : 2,018
Growth (%) : 2
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,428
2020 Revenue in Millions : 1,251
Growth (%) : 14
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 1,365
2021 Revenue in Millions : 1,428
Growth (%) : -4
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 2,414
2021 Revenue in Millions : 2,090
Growth (%) : 15
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 2,525
2022 Revenue in Millions : 2,414
Growth (%) : -1
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 1,463
2022 Revenue in Millions : 1,365
Growth (%) : 7
Main Therapeutic Indication : Immunology
Currency : USD
2024 Revenue in Millions : 1,643
2023 Revenue in Millions : 1,463
Growth (%) : 12
